298 related articles for article (PubMed ID: 36569883)
1. Omicron variants of SARS-CoV-2 and long COVID.
Yang C; Zhao H; Shannon CP; Tebbutt SJ
Front Immunol; 2022; 13():1061686. PubMed ID: 36569883
[TBL] [Abstract][Full Text] [Related]
2. Long-COVID Symptoms in Individuals Infected with Different SARS-CoV-2 Variants of Concern: A Systematic Review of the Literature.
Fernández-de-Las-Peñas C; Notarte KI; Peligro PJ; Velasco JV; Ocampo MJ; Henry BM; Arendt-Nielsen L; Torres-Macho J; Plaza-Manzano G
Viruses; 2022 Nov; 14(12):. PubMed ID: 36560633
[TBL] [Abstract][Full Text] [Related]
3. A Glycosylated RBD Protein Induces Enhanced Neutralizing Antibodies against Omicron and Other Variants with Improved Protection against SARS-CoV-2 Infection.
Shi J; Zheng J; Tai W; Verma AK; Zhang X; Geng Q; Wang G; Guan X; Malisheni MM; Odle AE; Zhang W; Li F; Perlman S; Du L
J Virol; 2022 Sep; 96(17):e0011822. PubMed ID: 35972290
[TBL] [Abstract][Full Text] [Related]
4. Evolution of the SARS-CoV-2 omicron variants BA.1 to BA.5: Implications for immune escape and transmission.
Shrestha LB; Foster C; Rawlinson W; Tedla N; Bull RA
Rev Med Virol; 2022 Sep; 32(5):e2381. PubMed ID: 35856385
[TBL] [Abstract][Full Text] [Related]
5. Boosting with Multiple Doses of mRNA Vaccine after Priming with Two Doses of Protein Subunit Vaccine MVC-COV1901 Elicited Robust Humoral and Cellular Immune Responses against Emerging SARS-CoV-2 Variants.
Chiu CH; Chang YH; Tao CW; Chang FY; Chiu KC; Chang TW; Yen LC
Microbiol Spectr; 2022 Oct; 10(5):e0060922. PubMed ID: 36005765
[TBL] [Abstract][Full Text] [Related]
6. SARS-CoV2 variant-specific replicating RNA vaccines protect from disease following challenge with heterologous variants of concern.
Hawman DW; Meade-White K; Archer J; Leventhal SS; Wilson D; Shaia C; Randall S; Khandhar AP; Krieger K; Hsiang TY; Gale M; Berglund P; Fuller DH; Feldmann H; Erasmus JH
Elife; 2022 Feb; 11():. PubMed ID: 35191378
[TBL] [Abstract][Full Text] [Related]
7. Comparison of Long COVID-19 Caused by Different SARS-CoV-2 Strains: A Systematic Review and Meta-Analysis.
Du M; Ma Y; Deng J; Liu M; Liu J
Int J Environ Res Public Health; 2022 Nov; 19(23):. PubMed ID: 36498103
[TBL] [Abstract][Full Text] [Related]
8. Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants.
Accorsi EK; Britton A; Fleming-Dutra KE; Smith ZR; Shang N; Derado G; Miller J; Schrag SJ; Verani JR
JAMA; 2022 Feb; 327(7):639-651. PubMed ID: 35060999
[TBL] [Abstract][Full Text] [Related]
9. Is Omicron the last SARS-CoV-2 Variant of Concern?
Rahimi F; Talebi Bezmin Abadi A
Arch Med Res; 2022 Apr; 53(3):336-338. PubMed ID: 35093242
[TBL] [Abstract][Full Text] [Related]
10. Emergency SARS-CoV-2 Variants of Concern: Novel Multiplex Real-Time RT-PCR Assay for Rapid Detection and Surveillance.
Chung HY; Jian MJ; Chang CK; Lin JC; Yeh KM; Chen CW; Hsieh SS; Hung KS; Tang SH; Perng CL; Chang FY; Wang CH; Shang HS
Microbiol Spectr; 2022 Feb; 10(1):e0251321. PubMed ID: 35196812
[TBL] [Abstract][Full Text] [Related]
11. Has Omicron Changed the Evolution of the Pandemic?
Lundberg AL; Lorenzo-Redondo R; Ozer EA; Hawkins CA; Hultquist JF; Welch SB; Prasad PVV; Oehmke JF; Achenbach CJ; Murphy RL; White JI; Havey RJ; Post LA
JMIR Public Health Surveill; 2022 Jan; 8(1):e35763. PubMed ID: 35072638
[TBL] [Abstract][Full Text] [Related]
12. Facing the Omicron variant-how well do vaccines protect against mild and severe COVID-19? Third interim analysis of a living systematic review.
Külper-Schiek W; Piechotta V; Pilic A; Batke M; Dreveton LS; Geurts B; Koch J; Köppe S; Treskova M; Vygen-Bonnet S; Waize M; Wichmann O; Harder T
Front Immunol; 2022; 13():940562. PubMed ID: 36091023
[TBL] [Abstract][Full Text] [Related]
13. Spotlights on the latest opinions on identification, prevention, and management of newer CoV-2 variants: A roundup appraisal on innovative ideas and designer vaccines for Omicron.
Seghatchian J; Pereira P; Lanza F
Transfus Apher Sci; 2022 Dec; 61(6):103499. PubMed ID: 35811273
[TBL] [Abstract][Full Text] [Related]
14. Neutralizing Activity Against SARS-CoV-2 Delta and Omicron Variants Following a Third BNT162b2 Booster Dose According to Three Homologous or Heterologous COVID-19 Vaccination Schedules.
Choi JY; Lee YJ; Ko JH; Kim SH; Kim HJ; Lee HW; Jeong H; Kim TY; Jang YG; Hong HJ; Kim MS; Lee SE; Kim YG; Chung EJ; Lim H; Jang S; Kim K; Kim SS; Ahn JY; Choi JY; Kim YC; Park YS; Peck KR; Kim B
Front Cell Infect Microbiol; 2022; 12():948014. PubMed ID: 35899050
[TBL] [Abstract][Full Text] [Related]
15. Risk of long COVID associated with delta versus omicron variants of SARS-CoV-2.
Antonelli M; Pujol JC; Spector TD; Ourselin S; Steves CJ
Lancet; 2022 Jun; 399(10343):2263-2264. PubMed ID: 35717982
[No Abstract] [Full Text] [Related]
16. Enhanced antibody responses in fully vaccinated individuals against pan-SARS-CoV-2 variants following Omicron breakthrough infection.
Jeong HW; Kim SM; Jung MK; Noh JY; Yoo JS; Kim EH; Kim YI; Yu K; Jang SG; Gil J; Casel MA; Rare R; Choi JH; Kim HS; Kim JH; Um J; Kim C; Kim Y; Chin BS; Jung S; Choi JY; Song KH; Kim YD; Park JS; Song JY; Shin EC; Choi YK
Cell Rep Med; 2022 Oct; 3(10):100764. PubMed ID: 36182684
[TBL] [Abstract][Full Text] [Related]
17. Origin, virological features, immune evasion and intervention of SARS-CoV-2 Omicron sublineages.
Xia S; Wang L; Zhu Y; Lu L; Jiang S
Signal Transduct Target Ther; 2022 Jul; 7(1):241. PubMed ID: 35853878
[TBL] [Abstract][Full Text] [Related]
18. Omicron variants escape the persistent SARS-CoV-2-specific antibody response in 2-year COVID-19 convalescents regardless of vaccination.
Wang M; Zhou B; Fan Q; Zhou X; Liao X; Lin J; Ma Z; Dong J; Wang H; Ge X; Ju B; Zhang Z
Emerg Microbes Infect; 2023 Dec; 12(1):2151381. PubMed ID: 36444724
[TBL] [Abstract][Full Text] [Related]
19. Estimated Protection of Prior SARS-CoV-2 Infection Against Reinfection With the Omicron Variant Among Messenger RNA-Vaccinated and Nonvaccinated Individuals in Quebec, Canada.
Carazo S; Skowronski DM; Brisson M; Sauvageau C; Brousseau N; Gilca R; Ouakki M; Barkati S; Fafard J; Talbot D; Gilca V; Deceuninck G; Garenc C; Carignan A; De Wals P; De Serres G
JAMA Netw Open; 2022 Oct; 5(10):e2236670. PubMed ID: 36239934
[TBL] [Abstract][Full Text] [Related]
20. A comprehensive analysis of the efficacy and effectiveness of COVID-19 vaccines.
He X; Su J; Ma Y; Zhang W; Tang S
Front Immunol; 2022; 13():945930. PubMed ID: 36090988
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
